Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - alprazolam - tablets sustained release - alprazolam 0.5 mg - alprazolam - for the treatment of anxiety and anxiety associated with depression.treatment of panic disorder with or without phobic avoidance

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - alprazolam - tablets sustained release - alprazolam 1 mg - alprazolam - for the treatment of anxiety and anxiety associated with depression. treatment of panic disorder with or without phobic avoidance

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - alprazolam - tablets sustained release - alprazolam 2 mg - alprazolam - for the treatment of anxiety and anxiety associated with depression. treatment of panic disorder with or without phobic avoidance

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - alprazolam - tablets sustained release - alprazolam 0.5 mg - alprazolam - alprazolam - for the treatment of anxiety and anxiety associated with depression.treatment of panic disorder with or without phobic avoidance

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - alprazolam - tablets sustained release - alprazolam 1 mg - alprazolam - alprazolam - for the treatment of anxiety and anxiety associated with depression. treatment of panic disorder with or without phobic avoidance

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - alprazolam - tablets sustained release - alprazolam 2 mg - alprazolam - alprazolam - for the treatment of anxiety and anxiety associated with depression. treatment of panic disorder with or without phobic avoidance

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - alprazolam (unii: yu55mq3izy) (alprazolam - unii:yu55mq3izy) - alprazolam 0.25 mg - xanax is indicated for the: xanax is contraindicated in patients: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including xanax, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/. neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see warnings and precautions (5.8) and clinical considerations)] . available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see data ). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adve

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - alprazolam (unii: yu55mq3izy) (alprazolam - unii:yu55mq3izy) - alprazolam 0.5 mg - xanax xr is indicated for the treatment of panic disorder with or without agoraphobia, in adults. xanax xr is contraindicated in patients: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including xanax xr, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/pregnancyregistry/. neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see warnings and precautions (5.8), and clinical considerations)] . available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see data ). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pre

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - alprazolam -

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 0.25mg (exclusive of 1.5% excess.);  ;   - tablet - 0.25 mg - active: alprazolam 0.25mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide [docusate sodium (85% ) with sodium benzoate [15%] lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.